Rolapitant for the prevention of delayed nausea and vomiting over initial and repeat courses of emetogenic chemotherapy

References

• Navari RM. The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Drug Saf. 2016;15:343–356.
   PubMed Web of Science ®Google Scholar
• Van laar ES, Desai JM, Jatoi A. Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2388 health care providers. Support Care Cancer. 2015;23:151–157.
   PubMed Web of Science ®Google Scholar
• Jordan K, Jahn F, Aapro M. Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol. 2015;26:1081–1090.
   PubMed Web of Science ®Google Scholar
• MASCC/ESMO. Antiemetic Guideline, 2016 v1.1. Hillerød, Denmark: Multinational Association of Supportive Care in Cancer; 2016.
   Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: antiemesis. Version 1. 2016. Available from: www.nccn.org. 2016.
   Google Scholar
• Hesketh PJ, Bohlke K, Lyman GH, et al. Antiemetics: American society of clinical oncology focused guideline update. J Clin Oncol. 2016;34:381–386.
   PubMed Web of Science ®Google Scholar
• Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358:2482–2494.
   PubMed Web of Science ®Google Scholar
• Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2011;29:4189–4198.
   PubMed Web of Science ®Google Scholar
• Aapro M, Molassiotis A, Dicato M, et al. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol. 2012;23:1986–1992.
   PubMed Web of Science ®Google Scholar
• Gilmore JW, Peacock NW, Gu A, et al. Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study. J Oncol Pract. 2014;10:68–74.
   PubMedGoogle Scholar
• Yu S, Burke TA, Chan A, et al. Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy–a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines. Support Care Cancer. 2015;23:273–282.
   PubMed Web of Science ®Google Scholar
• Jordan K, Gralla R, Jahn F, et al. International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol. 2014;722:197–202.
   PubMed Web of Science ®Google Scholar
• Burmeister H, Aebi S, Studer C, et al. Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting. Support Care Cancer. 2012;20:141–147.
   PubMed Web of Science ®Google Scholar
• Salsman JM, Grunberg SM, Beaumont JL, et al. Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives. J Natl Compr Canc Netw. 2012;10:149–157.
   PubMed Web of Science ®Google Scholar
• Hsieh RK, Chan A, Kim HK, et al. Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries. Support Care Cancer. 2015;23:263–272.
   PubMed Web of Science ®Google Scholar
• Ellebaek E, Herrstedt J. Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy. Curr Opin Support Palliat Care. 2008;2:28–34.
   PubMedGoogle Scholar
• Kim HK, Hsieh R, Chan A, et al. Impact of CINV in earlier cycles on CINV and chemotherapy regimen modification in subsequent cycles in Asia Pacific clinical practice. Support Care Cancer. 2015;23:293–300.
   PubMed Web of Science ®Google Scholar
• De Wit R, Herrstedt J, Rapoport B, et al. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur J Cancer. 2004;40:403–410.
   PubMed Web of Science ®Google Scholar
• De Wet M, Falkson G, Rapoport BL. Repeated use of granisetron in patients receiving cytostatic agents. Cancer. 1993;71:4043–4049.
   PubMed Web of Science ®Google Scholar
• Gandara DR. Progress in the control of acute and delayed emesis induced by cisplatin. Eur J Cancer. 1991;27(suppl 1):S9-11; discussion S22.
   PubMed Web of Science ®Google Scholar
• De wit R, Van den berg H, Burghouts J, et al. Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles. Br J Cancer. 1998;77:1487–1491.
   PubMed Web of Science ®Google Scholar
• De wit R, Schmitz PI, Verweij J, et al. Analysis of cumulative probabilities shows that the efficacy of 5HT3 antagonist prophylaxis is not maintained. J Clin Oncol. 1996;14:644–651.
   PubMed Web of Science ®Google Scholar
• Aogi K, Sakai H, Yoshizawa H, et al. A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy. Support Care Cancer. 2012;20:1507–1514.
   PubMed Web of Science ®Google Scholar
• Longo F, Mansueto G, Lapadula V, et al. Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy. Int J Clin Pract. 2012;66:753–757.
   PubMed Web of Science ®Google Scholar
• Choi BS, Borsaru GP, Ballinari G, et al. Multicenter phase IV study of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with non-Hodgkin lymphomas undergoing repeated cycles of moderately emetogenic chemotherapy. Leuk Lymphoma. 2014;55:544–550.
   PubMed Web of Science ®Google Scholar
• Boccia R, Cooper W, O’Boyle E. Sustained antiemetic responses with APF530 (sustained-release granisetron) during multiple cycles of emetogenic chemotherapy. J Community Support Oncol. 2015;13:38–46.
   PubMedGoogle Scholar
• De Wit R, Herrstedt J, Rapoport B, et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol. 2003;21:4105–4111.
   PubMed Web of Science ®Google Scholar
• Herrstedt J, Muss HB, Warr DG, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer. 2005;104:1548–1555.
   PubMed Web of Science ®Google Scholar
• Rapoport B, Schwartzberg L, Chasen M, et al. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy. Eur J Cancer. 2016;57:23–30.
   PubMed Web of Science ®Google Scholar
• Gralla RJ, Bosnjak SM, Hontsa A, et al. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol. 2014;25:1333–1339.
   PubMed Web of Science ®Google Scholar
• Ruhlmann CH, Christensen TB, Dohn LH, et al. Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial. Lancet Oncol. 2016;17:509–518.
   PubMed Web of Science ®Google Scholar
• Schnell FM, Coop AJ. An evaluation of potential signals for ventricular arrhythmia and cardiac arrest with dolasetron, ondansetron, and granisetron in the fda combined spontaneous reporting system/adverse event reporting system. Curr Ther Res Clin Exp. 2005;66:409–419.
   PubMed Web of Science ®Google Scholar
• Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009;10:115–124.
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin–the aprepitant protocol 052 study group. J Clin Oncol. 2003;21:4112–4119.
   PubMed Web of Science ®Google Scholar
• Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97:3090–3098.
   PubMed Web of Science ®Google Scholar
• Rapoport BL, Jordan K, Boice JA, et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer. 2010;18:423–431.
   PubMed Web of Science ®Google Scholar
• Grunberg S, Chua D, Maru A, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol–EASE. J Clin Oncol. 2011;29:1495–1501.
   PubMed Web of Science ®Google Scholar
• Molassiotis A, Aapro M, Dicato M, et al. Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. J Pain Symptom Manage. 2014;47(839–48):e4.
   Google Scholar
• Roila F, Boschetti E, Tonato M, et al. Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study. Am J Clin Oncol. 1991;14:238–242.
   PubMed Web of Science ®Google Scholar
• Feyer P, Jahn F, Jordan K. Radiation induced nausea and vomiting. Eur J Pharmacol. 2014;722:165–171.
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Rossi G, Rizzi G, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol. 2014;25:1340–1346.
   PubMed Web of Science ®Google Scholar
• Aapro M, Rugo H, Rossi G, et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol. 2014;25:1328–1333.
   PubMed Web of Science ®Google Scholar
• Aapro M, Karthaus M, Schwartzberg L, et al. Phase 3 study of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting during repeated moderately emetogenic chemotherapy (MEC) cycles. J Clin Oncol. 2014;32(suppl):Abstract 9502.
   Google Scholar
• Duffy RA, Morgan C, Naylor R, et al. Rolapitant (SCH 619734): a potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets. Pharmacol Biochem Behav. 2012;102:95–100.
   PubMed Web of Science ®Google Scholar
• Poma A, Christensen J, Davis J, et al. Phase 1 positron emission tomography (PET) study of the receptor occupancy of rolapitant, a novel NK-1 receptor antagonist. J Clin Oncol. 2014;32(suppl):Abstracte 20690.
   Google Scholar
• Varubi PI. Varubi [package insert]. Waltham, MA: Tesaro; 2015.
   Google Scholar
• Gan TJ, Gu J, Singla N, et al. Rolapitant for the prevention of postoperative nausea and vomiting: a prospective, double-blinded, placebo-controlled randomized trial. Anesth Analg. 2011;112:804–812.
   PubMed Web of Science ®Google Scholar
• Wang X, Wang J, Kansra V. Population pharmacokinetics of rolapitant in patients with chemotherapy-induced nausea and vomiting. Presented at European Cancer Congress. 25-29 September 2015; Vienna, Austria. Poster 1588.
   Google Scholar
• Emend PI. Emend [package insert]. Whitehouse NJ: Merck Sharp & Dohme Corp; 2015.
   Google Scholar
• Emend IVPI. Emend for injection [package insert]. Whitehouse NJ: Merck Sharp & Dohme Corp; 2016.
   Google Scholar
• Akynzea PI. Akynzeo [package insert]. Woodcliff Lake, NJ: Eisai Inc.; 2015.
   Google Scholar
• Poma A, Christensen J, Pertikis H, et al. Rolapitant and its major metabolite do not affect the pharmacokinetics of midazolam, a sensitive cytochrome P450 3A4 substrate. Support Care Cancer. 2013;21:S154. Abstract 441.
   Google Scholar
• Barbour S, Wang X, Poma A, et al. Low risk of drug interactions with rolapitant is coadministered with CYP2S6 or BCRP substrates: integrated safety results. Presented at European Cancer Congress. 25-29 September 2015; Vienna, Austria. Poster 1529.
   Google Scholar
• Rapoport B, Chua D, Poma A, et al. Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). Support Care Cancer. 2015;23:3281–3288.
   PubMed Web of Science ®Google Scholar
• Rapoport BL, Chasen MR, Gridelli C, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol. 2015;16:1079–1089.
   PubMed Web of Science ®Google Scholar
• Schwartzberg LS, Modiano MR, Rapoport BL, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial. Lancet Oncol. 2015;16:1071–1078.
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Schnadig ID, Schwartzberg LS, et al. Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy. Cancer. 2016;122:2418–2425.
   PubMed Web of Science ®Google Scholar
• Sommariva S, Pongiglione B, Tarricone R. Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review. Crit Rev Oncol Hematol. 2016;99:13–36.
   PubMed Web of Science ®Google Scholar
• Bosnjak SM, Dimitrijevic J, Djordjevic F. Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine. Curr Opin Support Palliat Care. 2016;10:180–188.
   PubMed Web of Science ®Google Scholar
• Chiu L, Chow R, Popovic M, et al. Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis. Support Care Cancer. 2016;24:2381–2392.
   PubMed Web of Science ®Google Scholar